<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="54573"><DrugName>dexamethasone (EyeGate II ocular inflammation therapy, iontophoresis delivery), EyeGate/ Bausch Health</DrugName><DrugNamesKey><Name id="42749906">dexamethasone</Name></DrugNamesKey><DrugSynonyms><Name><Value>dexamethasone</Value><Types><Type>BANN</Type><Type>INN</Type></Types></Name><Name><Value>OPT-014</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>methylprednisolone (EyeGate II ocular inflammation therapy, iontophoresis delivery), EyeGate</Value></Name><Name><Value>dexamethasone (EyeGate II ocular inflammation therapy, iontophoresis delivery), EyeGate</Value></Name><Name><Value>EGP-437</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>dexamethasone (EyeGate II ocular inflammation therapy, iontophoresis delivery), EyeGate/ Valeant</Value></Name><Name><Value>dexamethasone (EyeGate II ocular inflammation therapy, iontophoresis delivery), EyeGate/ Bausch Health</Value></Name><Name><Value>50-02-2</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="29773">Eyegate Pharmaceuticals Inc</CompanyOriginator><CompaniesPrimary><Company id="29773">Eyegate Pharmaceuticals Inc</Company></CompaniesPrimary><CompaniesSecondary><Company id="17058">Bausch Health Companies Inc</Company></CompaniesSecondary><CrossReferences><SourceEntity id="54573" type="Drug"><TargetEntity id="281034" type="siDrug">Dexamethasone sodium phosphate</TargetEntity></SourceEntity><SourceEntity id="17058" type="Company"><TargetEntity id="4295861031" type="organizationId">Valeant Pharmaceuticals International Inc</TargetEntity></SourceEntity><SourceEntity id="29773" type="Company"><TargetEntity id="4298129490" type="organizationId">EyeGate Pharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="20" type="ciIndication"><TargetEntity id="10033371" type="MEDDRA"></TargetEntity><TargetEntity id="D010146" type="MeSH"></TargetEntity><TargetEntity id="-1585850437" type="omicsDisease"></TargetEntity><TargetEntity id="1" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2497" type="ciIndication"><TargetEntity id="H15.0" type="ICD10"></TargetEntity><TargetEntity id="10039705" type="MEDDRA"></TargetEntity><TargetEntity id="D015423" type="MeSH"></TargetEntity><TargetEntity id="-53470526" type="omicsDisease"></TargetEntity><TargetEntity id="1631" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3016" type="ciIndication"><TargetEntity id="H04.12" type="ICD10"></TargetEntity><TargetEntity id="10048221" type="MEDDRA"></TargetEntity><TargetEntity id="D014985" type="MeSH"></TargetEntity><TargetEntity id="-455555105" type="omicsDisease"></TargetEntity><TargetEntity id="773" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3022" type="ciIndication"><TargetEntity id="10054846" type="MEDDRA"></TargetEntity><TargetEntity id="D016039" type="MeSH"></TargetEntity><TargetEntity id="-2088842439" type="omicsDisease"></TargetEntity><TargetEntity id="1084" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3352" type="ciIndication"><TargetEntity id="10025415" type="MEDDRA"></TargetEntity><TargetEntity id="D008269" type="MeSH"></TargetEntity><TargetEntity id="-1219194828" type="omicsDisease"></TargetEntity><TargetEntity id="775" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="341" type="ciIndication"><TargetEntity id="10046851" type="MEDDRA"></TargetEntity><TargetEntity id="D014605" type="MeSH"></TargetEntity><TargetEntity id="98715" type="ORPHANET"></TargetEntity><TargetEntity id="-1203341451" type="omicsDisease"></TargetEntity><TargetEntity id="798" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="686" type="ciIndication"><TargetEntity id="10015943" type="MEDDRA"></TargetEntity><TargetEntity id="783" type="siCondition"></TargetEntity><TargetEntity id="4686" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3191" type="Action"><TargetEntity id="1738" type="Mechanism">Glucocorticoid Receptor (GR) Agonists</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C3">Phase 3 Clinical</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="20">Pain</Indication><Indication id="3352">Macular edema</Indication><Indication id="341">Uveitis</Indication><Indication id="686">Ocular inflammation</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="2497">Scleritis</Indication><Indication id="3016">Xerophthalmia</Indication><Indication id="3022">Corneal transplantation</Indication></IndicationsSecondary><ActionsPrimary><Action id="3191">Glucocorticoid receptor agonist</Action></ActionsPrimary><ActionsSecondary><Action id="15133">Ophthalmological corticosteroid</Action><Action id="2946">Analgesic</Action><Action id="2954">Steroidal anti-inflammatory</Action></ActionsSecondary><Technologies><Technology id="764">Local formulation unspecified</Technology><Technology id="90">Steroid</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="620">Ophthalmic formulation</Technology></Technologies><EphmraCodes><Ephmra><Code>N2</Code><Name>ANALGESICS</Name></Ephmra><Ephmra><Code>S1B</Code><Name>OPHTHALMOLOGICAL CORTICOSTEROIDS</Name></Ephmra></EphmraCodes><LastModificationDate>2019-05-17T06:12:51.000Z</LastModificationDate><ChangeDateLast>2019-05-13T00:00:00.000Z</ChangeDateLast><AddedDate>2005-12-05T10:32:31.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="29773" linkType="Company"&gt;EyeGate Pharma&lt;/ulink&gt; is developing EGP-437, an ophthalmic reformulation of  the topically active steroid, dexamethasone,   delivered using the company's iontophoretic EyeGate II technology, for the potential treatment  of uveitis,  macular edema,  and post-operative pain and inflammation in ocular surgery patients, including those undergoing cataract surgery   [&lt;ulink linkID="925642" linkType="Reference"&gt;925642&lt;/ulink&gt;], [&lt;ulink linkID="788054" linkType="Reference"&gt;788054&lt;/ulink&gt;], [&lt;ulink linkID="896378" linkType="Reference"&gt;896378&lt;/ulink&gt;], [&lt;ulink linkID="1258005" linkType="Reference"&gt;1258005&lt;/ulink&gt;], [&lt;ulink linkID="1646447" linkType="Reference"&gt;1646447&lt;/ulink&gt;], [&lt;ulink linkID="1677542" linkType="Reference"&gt;1677542&lt;/ulink&gt;],   [&lt;ulink linkID="1774268" linkType="Reference"&gt;1774268&lt;/ulink&gt;], [&lt;ulink linkID="2053818" linkType="Reference"&gt;2053818&lt;/ulink&gt;], [&lt;ulink linkID="2070517" linkType="Reference"&gt;2070517&lt;/ulink&gt;], [&lt;ulink linkID="2126953" linkType="Reference"&gt;2126953&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2012, a phase III uveitis trial was initiated [&lt;ulink linkID="1252627" linkType="Reference"&gt;1252627&lt;/ulink&gt;]; in April 2013, topline data were reported [&lt;ulink linkID="1401881" linkType="Reference"&gt;1401881&lt;/ulink&gt;], [&lt;ulink linkID="1401643" linkType="Reference"&gt;1401643&lt;/ulink&gt;]. In January 2016,  a confirmatory phase III trial for non-infectious anterior uveitis was initiated [&lt;ulink linkID="1728145" linkType="Reference"&gt;1728145&lt;/ulink&gt;]; in April 2018, topline data were expected in 3Q18 and an NDA filing  was planned for   1H19 [&lt;ulink linkID="2020243" linkType="Reference"&gt;2020243&lt;/ulink&gt;]. In July 2017, a phase IIb trial was initiated in cataract surgery patients [&lt;ulink linkID="1939071" linkType="Reference"&gt;1939071&lt;/ulink&gt;]; in February 2018, negative topline results were reported; at that time, the company was reviewing these data to determine the next steps [&lt;ulink linkID="2002609" linkType="Reference"&gt;2002609&lt;/ulink&gt;]; in January 2017, an sNDA for post-cataract surgery pain and inflammation was expected to be filed in 2H18 [&lt;ulink linkID="1894465" linkType="Reference"&gt;1894465&lt;/ulink&gt;]. In July 2015, the first patient was dosed in a phase Ib/IIa trial for macular edema [&lt;ulink linkID="1677542" linkType="Reference"&gt;1677542&lt;/ulink&gt;], [&lt;ulink linkID="1677642" linkType="Reference"&gt;1677642&lt;/ulink&gt;]; in November 2015, interim data from the trial were reported [&lt;ulink linkID="1710408" linkType="Reference"&gt;1710408&lt;/ulink&gt;]; in February 2018, further clinical development of the drug for the treatment macular edema was being assessed [&lt;ulink linkID="2014000" linkType="Reference"&gt;2014000&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;EGP-437 was previously being developed for the potential treatment of dry eye syndrome (DES) and scleritis, and investigated for the potential treatment of corneal graft rejection [&lt;ulink linkID="1166827" linkType="Reference"&gt;1166827&lt;/ulink&gt;]. In June 2010, a phase III  dry eye  trial was initiated in the US  [&lt;ulink linkID="1110565" linkType="Reference"&gt;1110565&lt;/ulink&gt;], [&lt;ulink linkID="1110401" linkType="Reference"&gt;1110401&lt;/ulink&gt;]; by December 2013, data were reported [&lt;ulink linkID="1515391" linkType="Reference"&gt;1515391&lt;/ulink&gt;]. In November 2010, a phase I trial in patients with scleritis was initiated    [&lt;ulink linkID="1258007" linkType="Reference"&gt;1258007&lt;/ulink&gt;]. However, by December 2017, no development had been reported for some time and it was presumed development in these indications had been discontinued.  &lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;EyeGate owns a delivery system patent portfolio consisting of seven patent families and including 15 US patents and 87 international patents, due to expire between 2018 and 2034. Through EyeGate's fully owned subsidiary &lt;ulink linkID="29773" linkType="Company"&gt;EyeGate Pharma S.A.S&lt;/ulink&gt;, a further 103 patents are held [&lt;ulink linkID="2014000" linkType="Reference"&gt;2014000&lt;/ulink&gt;]. &lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;In January 2017, a supplemental NDA for post cataract surgery pain and inflammation was expected to be filed in 2H18 [&lt;ulink linkID="1894465" linkType="Reference"&gt;1894465&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2015, the FDA guided that positive data from the proposed phase III trial along with data from a previously completed phase III trial in anterior uveitis and the non-clinical work completed to date would be sufficient to support a NDA filing. At that time, based on positive feedback the company elected to cancel the face-to-face portion of the type B meeting scheduled for May 05, 2015 [&lt;ulink linkID="1656208" linkType="Reference"&gt;1656208&lt;/ulink&gt;]. In April 2018,  an NDA filing  was planned for   1H19 [&lt;ulink linkID="2020243" linkType="Reference"&gt;2020243&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2008, the drug was awarded Orphan status by the FDA for corneal graft rejection [&lt;ulink linkID="1258005" linkType="Reference"&gt;1258005&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In April 2009, the EMEA's COMP adopted a positive opinion on granting Orphan status to an iontophoretic dexamethasone formulation, presumed to be EGP-437, for corneal graft rejection [&lt;ulink linkID="999228" linkType="Reference"&gt;999228&lt;/ulink&gt;]. In May 2009, the Orphan status had been granted [&lt;ulink linkID="1258005" linkType="Reference"&gt;1258005&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Dry Eye&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In January 2010, a pivotal study for dry eye was expected to begin in the first half of 2010 [&lt;ulink linkID="1067361" linkType="Reference"&gt;1067361&lt;/ulink&gt;]; in March 2010, the multicenter, phase III trial was expected to begin in the second half of 2010 [&lt;ulink linkID="1085462" linkType="Reference"&gt;1085462&lt;/ulink&gt;]. In June 2010, the randomized, double-blind, placebo-controlled, parallel-assignment, safety or efficacy phase III trial (ALLUVION; &lt;ulink linkID="66663" linkType="Protocol"&gt;NCT01129856&lt;/ulink&gt;; EGP-437-003) was initiated in patients (expected n = 180) with dry eye in the US. The study was expected to be completed in April 2011 [&lt;ulink linkID="1110565" linkType="Reference"&gt;1110565&lt;/ulink&gt;],   [&lt;ulink linkID="1110401" linkType="Reference"&gt;1110401&lt;/ulink&gt;].  In November 2010, the trial was still recruiting [&lt;ulink linkID="1144700" linkType="Reference"&gt;1144700&lt;/ulink&gt;]. In January 2011,  enrollment was  completed with  top-line data expected by the end of     the first quarter of 2011 [&lt;ulink linkID="1159017" linkType="Reference"&gt;1159017&lt;/ulink&gt;]. In   April 2011, the 9-week 198-patient trial was completed     [&lt;ulink linkID="1110565" linkType="Reference"&gt;1110565&lt;/ulink&gt;]. By December 2013, data were available, demonstrating that EGP-437 significantly improved dry eye signs and symptoms relative to placebo in controlled adverse environment (CAE) challenge, CAE recovery and environmental conditions, which suggested a rapid onset of action and long-lasting effect of the drug [&lt;ulink linkID="1515391" linkType="Reference"&gt;1515391&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In November 2008, the company began enrollment in a US, phase II dry eye trial (&lt;ulink linkID="31793" linkType="Protocol"&gt;NCT00765804&lt;/ulink&gt;; EGP-437-002). In the single-center, randomized, double-masked, placebo-controlled, safety and efficacy study, 80 patients would receive one of two doses of EGP-437 for 3 weeks. At that time, results were expected in early 2009 [&lt;ulink linkID="961558" linkType="Reference"&gt;961558&lt;/ulink&gt;], [&lt;ulink linkID="962359" linkType="Reference"&gt;962359&lt;/ulink&gt;]. The trial was completed in March 2009, with 89 patients enrolled. The company expected to report results in the second quarter of that year [&lt;ulink linkID="988919" linkType="Reference"&gt;988919&lt;/ulink&gt;]. Results were reported in June 2009. EGP-437 improved the signs and symptoms of the disease in 105 patients. Improvement was observed during and after CAE exposure and within hours of dosing. EGP-437 also improved post-CAE recovery [&lt;ulink linkID="1015296" linkType="Reference"&gt;1015296&lt;/ulink&gt;]. In October 2009, the company planned to present further data at the  Annual Meeting of the American  Academy of Ophthalmology in San Francisco, CA, later   that month   [&lt;ulink linkID="1050092" linkType="Reference"&gt;1050092&lt;/ulink&gt;]. By June 2010,  the data had been   submitted to the FDA as part of an end-of-phase II meeting [&lt;ulink linkID="1110401" linkType="Reference"&gt;1110401&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Uveitis&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In March 2015, the company planned for a confirmatory phase III trial in anterior uveitis [&lt;ulink linkID="1646447" linkType="Reference"&gt;1646447&lt;/ulink&gt;]. In May 2015, the company planned to initiate the prospective, multicenter, randomized, double-masked, parallel-arm, positive control non-inferiority, phase III trial in patients (expected n = 250) with non-infectious anterior segment uveitis at approximately 60 US sites to evaluate EGP-437 compared to standard of care, prednisolone acetate ophthalmic suspension (1%). At that time, the FDA accepted the trial design [&lt;ulink linkID="1656208" linkType="Reference"&gt;1656208&lt;/ulink&gt;]. In January 2016, first patient was enrolled in the trial (&lt;ulink linkID="236849" linkType="Protocol"&gt;NCT02517619&lt;/ulink&gt;; EGP-437-006) [&lt;ulink linkID="1728145" linkType="Reference"&gt;1728145&lt;/ulink&gt;]. In April 2018, patient enrollment was completed with 250 patients enrolled, and topline data were expected in 3Q18 [&lt;ulink linkID="2020243" linkType="Reference"&gt;2020243&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In January 2012, first patient was enrolled in a randomized, double-masked, positive-controlled, non-inferiority, pivotal efficacy phase III trial of EGP-437 compared with prednisolone acetate eye drops in subjects (expected n = 200) was initiated in US [&lt;ulink linkID="1252627" linkType="Reference"&gt;1252627&lt;/ulink&gt;]; in December 2012, patient enrollment was completed [&lt;ulink linkID="1351299" linkType="Reference"&gt;1351299&lt;/ulink&gt;]. In April 2013, top-line data were reported from the 193-patient, phase III study (&lt;ulink linkID="83808" linkType="Protocol"&gt;NCT01505088&lt;/ulink&gt;, EGP-437-004). On day 14, the primary end point of anterior chamber cell score was zero. Data demonstrated that response rate to the two iontophoretic treatments of EGP-437 (32 complete responses out of 96 patients) and 1% prednisolone acetate (32 complete responses out of 97 patients) were same on day 14 [&lt;ulink linkID="1401881" linkType="Reference"&gt;1401881&lt;/ulink&gt;], [&lt;ulink linkID="1401643" linkType="Reference"&gt;1401643&lt;/ulink&gt;].  By March 2015, the trial was completed [&lt;ulink linkID="1646447" linkType="Reference"&gt;1646447&lt;/ulink&gt;]. By February 2018, data had been reported showing that although the same response rate was achieved,  the   EGP-437  dose  tested was  outside the pre-set non-inferiority margin for intent-to-treat and per protocol populations and did not achieve statistical significance in the intent-to-treat population [&lt;ulink linkID="2014000" linkType="Reference"&gt;2014000&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In June 2008, EyeGate started a phase I/II trial of EGP-437 for non-infectious acute anterior segment uveitis. The multicenter, randomized, double-blind, US, proof-of-concept, 40-patient trial (&lt;ulink linkID="18517" linkType="Protocol"&gt;NCT00694135&lt;/ulink&gt;, EGP-437-001) would assess the safety, tolerability and efficacy of four transcleral iontophoretic doses of EGP-437. The primary endpoint was anterior chamber cell score, and the secondary endpoints included anterior chamber flare, other slit lamp findings, ocular pain, best corrected visual acuity and adverse events. Patient enrollment began in July 2008, and the trial was expected to complete in February 2009 [&lt;ulink linkID="925642" linkType="Reference"&gt;925642&lt;/ulink&gt;], [&lt;ulink linkID="925579" linkType="Reference"&gt;925579&lt;/ulink&gt;]. In October 2009,  the trial was completed [&lt;ulink linkID="1050092" linkType="Reference"&gt;1050092&lt;/ulink&gt;]. In March 2010, data from the trial were reported demonstrating EGP-437  reduced anterior chamber cell (ACC) score to 0 within 2 weeks of a single administration in half the patients treated, and at day 28, the majority of participants had achieved a score of 0 and required no further treatment. No significant changes in intraocular pressure or signs of 	formation were seen. At that time, the data were submitted to the FDA as part of an end-of-phase II meeting [&lt;ulink linkID="1085462" linkType="Reference"&gt;1085462&lt;/ulink&gt;]. In May 2010, similar clinical data were presented at the 2010 ARVO Annual Meeting in Fort Lauderdale, FL. The  highest proportion of subjects with an anterior chamber cell score and count of 0 were found in the 1.6 mA/min group [&lt;ulink linkID="1092784" linkType="Reference"&gt;1092784&lt;/ulink&gt;]; in January 2012, the company reported, similar data would be published later that month [&lt;ulink linkID="1252627" linkType="Reference"&gt;1252627&lt;/ulink&gt;]; later that month, the data were published. The data demonstrated ACC score of zero was achieved in 48% of patients at day 14 with reduction of ACC score from baseline in 65% of patients at day 28. The mean intraocular pressure was within normal range with mean best-corrected visual acuity at 4 meters was relatively stable. Pharmacokinetics data showed low short-term systemic exposure to dexamethasone after iontophoresis [&lt;ulink linkID="1351299" linkType="Reference"&gt;1351299&lt;/ulink&gt;], [&lt;ulink linkID="1351462" linkType="Reference"&gt;1351462&lt;/ulink&gt;]. In December 2016, data from third stage of  the trial which enrolled 30 patients were reported. A positive response, determined by a reduction in  ACC  count, was observed in patients in both of the EGP-437 treatment arms. Patients administered with 4.5 mA-min dosing (3.0 mA for 1.5 min) realized the greatest benefit, with 30  and 80% of patients at day 14 and   28 respectively, achieving complete reduction or an ACC count of zero. The placebo cohort required 80% of patients to be rescued prior to day 14 and only 10% had an ACC count of zero on day 28. The procedure was very well tolerated in all subjects. Patients receiving EGP-437 at both dosing levels experienced reduced pain at all time points, with 70% of patients having a pain score of zero as early as day 1 versus the placebo cohort  (10% achieved a pain score of zero at day 1) [&lt;ulink linkID="1882342" linkType="Reference"&gt;1882342&lt;/ulink&gt;].		&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Cataract surgery&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In August 2016, a randomized, placebo-controlled phase II trial of EGP-437 in cataract surgery patients with pain and inflammation was planned [&lt;ulink linkID="1787317" linkType="Reference"&gt;1787317&lt;/ulink&gt;], [&lt;ulink linkID="1894465" linkType="Reference"&gt;1894465&lt;/ulink&gt;]. In July 2017, a  double masked, multicenter, placebo controlled, parallel assigned, phase IIb trial (&lt;ulink linkID="301426" linkType="Protocol"&gt;NCT03180255&lt;/ulink&gt;; EGP-437-009) was initiated in the US in patients (expected n = 100) having undergone cataract surgery with implantation of a posterior chamber intraocular lens to assess the efficacy and safety of transcleral iontophoretic delivery of dexamethasone phosphate ophthalmic solution. The trial was expected to complete in January 2018 [&lt;ulink linkID="1939071" linkType="Reference"&gt;1939071&lt;/ulink&gt;]. In August 2017, the first patient was enrolled in the trial   [&lt;ulink linkID="1949864" linkType="Reference"&gt;1949864&lt;/ulink&gt;]. In November 2017, enrollment was completed  [&lt;ulink linkID="1979915" linkType="Reference"&gt;1979915&lt;/ulink&gt;]. In February 2018, negative topline data were reported. EGP-437 demonstrated a higher rate of success compared with vehicle at all time points. However, the co-primary endpoints of proportion of subjects with an ACC count of zero at day 7 and the proportion of subjects with a pain score of zero at day 1 did not show statistical significance. The drug demonstrated a safety profile with no serious adverse events reported; at that time, the company was reviewing these data to determine the next steps [&lt;ulink linkID="2002609" linkType="Reference"&gt;2002609&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By May 2016, a phase Ib/IIa trial in ocular inflammation and pain post cataract surgery was initiated. At that time, top-line data were expected in the second quarter of 2016 [&lt;ulink linkID="1762524" linkType="Reference"&gt;1762524&lt;/ulink&gt;]. In June 2016, interim data from the trial were reported. Data demonstrated that positive response was observed in the majority of the patients, with some patients in 9.0 and 14.0 mA-min cohorts presenting with anterior chamber cell count (ACC) of zero at day 14 and others presenting with trace ACC levels. Additionally, all subjects experienced low pain throughout the duration of the trial [&lt;ulink linkID="1768415" linkType="Reference"&gt;1768415&lt;/ulink&gt;]. In July 2016, topline data from the 40-subject trial were reported. A positive response, determined by reduction in Anterior Chamber Cell count (ACC) at day 28, was observed in the majority of patients in cohort 4. Subjects receiving the 14 mA-min dose at days 0, 1 and 4 demonstrated the most significant ACC improvement, with 40% of subjects in this cohort achieving an ACC count of 0 at day 14 which increased to 88% on day 28. All treated subjects    experienced reduction in pain at all time points with 90% having no pain as early as day 01 and increasing to 100% on day 14 again in this 14 mA-min cohort.  Top-line data from the additional cohorts were expected  in the fourth quarter of 2016 [&lt;ulink linkID="1784637" linkType="Reference"&gt;1784637&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In November 2015, an open-label, multi-center, single group assigned,  phase I/IIa  trial (&lt;ulink linkID="242633" linkType="Protocol"&gt;NCT02571556&lt;/ulink&gt;; EGP-437-008) was initiated in the US, to assess the safety and efficacy of EGP-437 in patients (expected n = 50) having undergone cataract surgery with implantation of a posterior chamber intraocular lens (iol). At that time, the trial was to complete in July 2016 [&lt;ulink linkID="1774268" linkType="Reference"&gt;1774268&lt;/ulink&gt;]. In May 2017, clinical data were presented at the 2017 ARVO Meeting in Baltimore, MD. At day 14,  ACC of 0 at day 14 after iontophoretic dose and treatment regimens (primary endpoint) was achieved by 20% of patients in placebo group, while a larger percentage of patients achieved ACC of 0 in cohorts 2 and 6 (30% and 40% of patients, respectively); and at day 28 ACC of 0 was achieved by a total of 80 and 70% of patients in cohorts 2 and 6, respectively. On day 1, pain score of zero was achieved by a majority of patients in cohorts 1 to 7. Further, in cohorts 1 to 7, the EGP-437 delivery was well tolerated, and elevation of intra-ocular pressure was not observed [&lt;ulink linkID="1925521" linkType="Reference"&gt;1925521&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In May 2012, a randomized, parallel-assignment, double-blind, placebo-controlled, phase II trial (&lt;ulink linkID="87599" linkType="Protocol"&gt;NCT01602068&lt;/ulink&gt;; EGP-437-005) was initiated in the US to to evaluate the safety and efficacy of ocular iontophoresis with EGP-437 compared with placebo in patients (n = 42) undergoing cataract surgery with implantation of a posterior chamber intraocular lens. The trial completed in October 2012 [&lt;ulink linkID="1993975" linkType="Reference"&gt;1993975&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Scleritis&lt;/subtitle&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In November 2010, a randomized, double-masked, dose-ranging, parallel-assignment phase I study (&lt;ulink linkID="63816" linkType="Protocol"&gt;NCT01059955&lt;/ulink&gt;; EGP-IST-001) was initiated in  patients (n = 24) with non-infections, non-necrotizing anterior scleritis. At that time, the study was expected to be completed by October 2012 [&lt;ulink linkID="1258007" linkType="Reference"&gt;1258007&lt;/ulink&gt;]. In January 2012, the study was ongoing  [&lt;ulink linkID="1258005" linkType="Reference"&gt;1258005&lt;/ulink&gt;]. In February 2012,  enrollment began in the placebo-controlled trial which would evaluate the  safety and tolerability of three ocular iontophoresis dose levels of the drug [&lt;ulink linkID="1267536" linkType="Reference"&gt;1267536&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Macular edema&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In March 2015, the company planned for a phase II trial in macular edema [&lt;ulink linkID="1646447" linkType="Reference"&gt;1646447&lt;/ulink&gt;]. In July 2015, the first patient was dosed in an open-label, multicenter, single group assignment  phase Ib/IIa  trial (&lt;ulink linkID="233505" linkType="Protocol"&gt;NCT02485249&lt;/ulink&gt;;  EGP-437-007)  to assess the safety and efficacy of iontophoretic dexamethasone phosphate ophthalmic solution in  patients (expected n  = 20)   with macular edema in the US. At that time, the trial was expected to be completed in March 2016 [&lt;ulink linkID="1677542" linkType="Reference"&gt;1677542&lt;/ulink&gt;], [&lt;ulink linkID="1677642" linkType="Reference"&gt;1677642&lt;/ulink&gt;]. In November 2015, interim data from the trial were reported. In the trial, EGP-437 was administered in three treatments at 14.0 mA-min (3.5mA) on day 0, 4 and 9 with Ozurdex administered as control. Data demonstrated that a positive response was observed in some of the patients, with pseudophakic eyes (an eye implanted with an intraocular lens) responding better than phakic eyes(an eye with a natural lens). Also, the drug was safe and well-tolerated. At that time, an extension to the trial was planned that would recruit an additional 15 patients with a modified dosing regimen, three consecutive days at the same iontophoretic dosage was to be initiated by the end of 2015 and additional data from the extension of this trial was expected in mid-2016 [&lt;ulink linkID="1710408" linkType="Reference"&gt;1710408&lt;/ulink&gt;]. In May 2016,  topline data were expected in the second quarter of 2016 [&lt;ulink linkID="1762524" linkType="Reference"&gt;1762524&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In April 2008, EyeGate began a phase I trial of its EyeGate II ocular drug delivery system. The single-center, randomized, single-masked, comparative-group, safety and tolerability study would assess single iontophoretic dose levels with a citrate buffer in 95 healthy volunteers [&lt;ulink linkID="896378" linkType="Reference"&gt;896378&lt;/ulink&gt;]. In November 2008, the trial was expected to complete by the end of the year [&lt;ulink linkID="961558" linkType="Reference"&gt;961558&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2007, phase I data were presented at the 4th IBC Ocular Anti-angiogenesis conference in Cambridge, MA. In the study, which was designed to assess the safety, tolerability, and efficacy of EyeGate's first-generation iontophoretic drug delivery device, 89 ocular inflammation patients that were refractory to topical steroids received a total of 216 applications of methylprednisolone delivered by iontophoresis. After three daily administrations, efficacy was observed by day 10 and maintained for at least 30 days, with 85% of patients reporting no or little pain. High pain was reported in some corneal graft patients. An improvement in visual acuity (from 20/400 to 20/125, no patients losing vision) was observed. The treatment was well tolerated and no cases of increased ocular pressure were reported [&lt;ulink linkID="788054" linkType="Reference"&gt;788054&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By October 2005, the program was expected to enter the clinic in 2006 [&lt;ulink linkID="630360" linkType="Reference"&gt;630360&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Corneal transplantation&lt;/subtitle&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In January 2009, a pivotal clinical trial for corneal graft rejection was expected to begin in 2009  [&lt;ulink linkID="975443" linkType="Reference"&gt;975443&lt;/ulink&gt;]. By February 2011, the company was planning to initiate a single or multi-centered, randomized, double-masked, placebo-controlled, safety and efficacy phase II clinical study for corneal graft rejection [&lt;ulink linkID="1166827" linkType="Reference"&gt;1166827&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In May 2011, preclinical data were presented at the 2011 ARVO Annual Meeting in Fort Lauderdale, FL. In a study of chronic (6-month) dosing via ocular iontophoresis in rabbits, the drug was well tolerated, with no significant clinical observations related to treatment  [&lt;ulink linkID="1183520" linkType="Reference"&gt;1183520&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;EyeGate technology is based on transcleral iontophoresis to deliver non-invasively a constant amount of drug to the posterior chamber of the eye in a 3-min treatment session [&lt;ulink linkID="630360" linkType="Reference"&gt;630360&lt;/ulink&gt;]. &lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="29773">Eyegate Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="341">Uveitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-01-05T00:00:00.000Z</StatusDate><Source id="1252627" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29773">Eyegate Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="686">Ocular inflammation</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-05-31T00:00:00.000Z</StatusDate><Source id="1993975" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29773">Eyegate Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3352">Macular edema</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-07-14T00:00:00.000Z</StatusDate><Source id="1677542" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29773">Eyegate Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-05-31T00:00:00.000Z</StatusDate><Source id="1993975" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17058">Bausch Health Companies Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="686">Ocular inflammation</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-03-14T00:00:00.000Z</StatusDate><Source id="2126953" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17058">Bausch Health Companies Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="341">Uveitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-03-14T00:00:00.000Z</StatusDate><Source id="2126953" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="17058">Bausch Health Companies Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="6">Deal Termination/Company Bankruptcy</DiscontinuedReason><Indication id="20">Pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2019-03-14T00:00:00.000Z</StatusDate><Source id="2126953" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29773">Eyegate Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3016">Xerophthalmia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-28T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29773">Eyegate Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="2497">Scleritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-28T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29773">Eyegate Pharmaceuticals Inc</Company><Country id="FR">France</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3022">Corneal transplantation</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-12-28T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="29773">Eyegate Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="341">Uveitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-06-05T00:00:00.000Z</StatusDate><Source id="925642" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29773">Eyegate Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3016">Xerophthalmia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-11-10T00:00:00.000Z</StatusDate><Source id="961558" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29773">Eyegate Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3352">Macular edema</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-31T00:00:00.000Z</StatusDate><Source id="1646447" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29773">Eyegate Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="2497">Scleritis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-11-30T00:00:00.000Z</StatusDate><Source id="1258007" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29773">Eyegate Pharmaceuticals Inc</Company><Country id="FR">France</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3022">Corneal transplantation</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-01-09T00:00:00.000Z</StatusDate><Source id="975443" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29773">Eyegate Pharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3016">Xerophthalmia</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-06-04T00:00:00.000Z</StatusDate><Source id="1110565" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17058">Bausch Health Companies Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="341">Uveitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-07-09T00:00:00.000Z</StatusDate><Source id="1676973" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17058">Bausch Health Companies Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="686">Ocular inflammation</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-02-21T00:00:00.000Z</StatusDate><Source id="1901968" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="17058">Bausch Health Companies Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="20">Pain</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-02-21T00:00:00.000Z</StatusDate><Source id="1901968" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29773">Eyegate Pharmaceuticals Inc</Company><Country id="FR">France</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="686">Ocular inflammation</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2005-10-25T00:00:00.000Z</StatusDate><Source id="630360" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29773">Eyegate Pharmaceuticals Inc</Company><Country id="FR">France</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="686">Ocular inflammation</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2007-04-16T00:00:00.000Z</StatusDate><Source id="788054" type="CONFERENCE"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="29773">Eyegate Pharmaceuticals Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="3022">Corneal transplantation</Indication><AwardedIndication>Treatment of corneal graft rejection</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="5">Transfer of Ownership</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-05-31T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="29773">Eyegate Pharmaceuticals Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="3022">Corneal transplantation</Indication><AwardedIndication>Treatment of corneal graft rejection</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="5">Transfer of Ownership</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2010-09-30T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="29773">Eyegate Pharmaceuticals Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="3022">Corneal transplantation</Indication><AwardedIndication>Treatment of corneal graft rejection</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-04-15T00:00:00.000Z</MileStoneDate><Source id="1258005" type="CORPORATE"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="29773">Eyegate Pharmaceuticals Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="3022">Corneal transplantation</Indication><AwardedIndication>Treatment of corneal graft rejection</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-02-05T00:00:00.000Z</MileStoneDate><Source id="999228" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="29773">Eyegate Pharmaceuticals Inc</OwnerCompany><Country id="US">US</Country><Indication id="3022">Corneal transplantation</Indication><AwardedIndication>Treatment of corneal graft rejection.</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-12-02T00:00:00.000Z</MileStoneDate><Source id="1258005" type="CORPORATE"></Source></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-00822"><Name>Glucocorticoid receptor</Name><SwissprotNumbers><Swissprot>O13186</Swissprot><Swissprot>O46567</Swissprot><Swissprot>O73673</Swissprot><Swissprot>P04150</Swissprot><Swissprot>P06536</Swissprot><Swissprot>P06537</Swissprot><Swissprot>P35547</Swissprot><Swissprot>P49115</Swissprot><Swissprot>P49843</Swissprot><Swissprot>P49844</Swissprot><Swissprot>P59667</Swissprot><Swissprot>P79269</Swissprot><Swissprot>P79686</Swissprot><Swissprot>Q5R9P5</Swissprot><Swissprot>Q95267</Swissprot><Swissprot>Q9N1U3</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2131612" linkType="reference" linkID="2131612"&gt;2131612&lt;/ulink&gt;]
							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="17058">Bausch Health Companies Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20516">US Government</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="20596">Johns Hopkins University</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="20658">University of Pennsylvania</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="29773">Eyegate Pharmaceuticals Inc</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>4</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="7">Drug - Development Services</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C</Smiles></StructureSmiles><Deals><Deal id="132936" title="US government to fund EyeGate Pharma's EGP-437 and drug delivery devices development programs"></Deal><Deal id="140477" title="University of Pennsylvania to receive FDA orphan drug indication grant for phase I study of EGP-437 in patients with anterior scleritis"></Deal><Deal id="140491" title="University of Pennsylvania to conduct phase I study for EyeGate Pharma's EGP-437 in patients with anterior scleritis"></Deal><Deal id="140492" title="Johns Hopkins University School of Medicine to conduct phase I study for EyeGate Pharma's EGP-437 in patients with anterior scleritis"></Deal><Deal id="155316" title="Valeant to acquire worldwide commercial rights and ex-US development rights to Eyegate's EGP-437 against uveitis      "></Deal></Deals><PatentFamilies><PatentFamily id="1119863" number="WO-2011041373" title="Positively-charged poly (D,L-lactide-co-glycolide) nanoparticles and fabrication methods of the same"></PatentFamily><PatentFamily id="1755748" number="WO-2009108626" title="Enhanced delivery of a therapeutic to ocular tissues through iontophoresis"></PatentFamily><PatentFamily id="675579" number="WO-2011041377" title="Ocular iontophoresis of charged micelles containing bioactive agents"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>3</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bausch Health Companies Inc" id="17058"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Eyegate Pharmaceuticals Inc" id="29773"></CompanyLink><CountAsOwner>3</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>3</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>Y</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>